echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JAHA: plasma human chondroprotein-39 is associated with the prognosis of acute ischemic stroke

    JAHA: plasma human chondroprotein-39 is associated with the prognosis of acute ischemic stroke

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Human chondroprotein-39 (YKL-40) is an inflammatory biomarker that has been reported to be involved in the developmental process


    Recently, the authoritative journal in the field of cardiovascular diseases, JAHA, published a research article, which aims to explore the prognostic value


    The researchers measured plasma YKL‐40 levels in 3377 participants in the Chinese Acute Ischemic Stroke Antihypertensive Treatment Trial (CATIS) and collected data on the outcome of


    During the 3-month follow-up period, 828 participants (24.


    Thus, the elevated level of YKL‐40 in the acute phase of ischemic stroke is associated with an increased risk of death and major disability 3 months after stroke, suggesting that YKL‐40 may be an important indicator


    Original Source:

    Tian Xu.
    et al.
    Plasma Human Cartilage Glycoprotein‐39 Is Associated With the Prognosis of Acute Ischemic Stroke.
    JAHA.
    2022.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.